Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Radiation Injuries 2Small Cell Lung Carcinoma 1Pinealoma 1Pain 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Meningioma 1Memory Disorders 1Medulloblastoma 1Lung Neoplasms 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Fatigue 1Ependymoma 1Depression 1Delirium 1Craniopharyngioma 1Cognitive Dysfunction 1Choroid Plexus Neoplasms 1Cancer Pain 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 149Docetaxel 139Paclitaxel 127Trastuzumab 120Tamoxifen 110Capecitabine 104Letrozole 92Epirubicin 79Doxorubicin 70Anastrozole 70exemestane 67Fulvestrant 65Fluorouracil 61Radiotherapy 60pertuzumab 40Gemcitabine 39Carboplatin 38Vinorelbine 34Goserelin 34Bevacizumab 29Zoledronic Acid 28Methotrexate 28Chemotherapy, Adjuvant 28eribulin 27Lapatinib 25ribociclib 24palbociclib 24Drug Therapy 22130-nm albumin-bound paclitaxel 20pegfilgrastim 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Breast Neoplasms × Donepezil × Clear all
NCT02822573 2023-09-13

Remember

Wake Forest University Health Sciences

Phase 3 Completed
276 enrolled 33 charts
Breast

Breast Neoplasms, Memory Disorders, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡